Literature DB >> 10602738

Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.

H Hvidberg1, C Struve, K A Krogfelt, N Christensen, S N Rasmussen, N Frimodt-Møller.   

Abstract

A model of ascending unobstructed urinary tract infection (UTI) in mice was developed to study the significance of the antibiotic concentration in urine, serum, and kidney tissue for efficacy of treatment of UTI in general and pyelonephritis in particular. Outbred Ssc-CF1 female mice were used throughout the study, and Escherichia coli was used as the pathogen. The virulence of 11 uropathogenic E. coli isolates and 1 nonpathogenic laboratory E. coli strain was examined. Strain C175-94 achieved the highest counts in the kidneys, and this strain was subsequently used as the infecting organism. The model gave reproducible bladder infections, i.e., bacteria were recovered from 22 of 23 control mice after 3 days, and histological examination of kidney tissue showed that of 14 infected kidneys, 7 (50%) showed major histological changes, whereas 3 of 36 uninfected kidneys showed major histological changes (P = 0.018). Once the model was established, the efficacies of different doses of cefuroxime and gentamicin, corresponding to active concentrations in urine only or in urine, serum, and kidney tissue simultaneously, were examined. All cefuroxime doses resulted in significantly lower counts in urine than control treatments, but the dose which produced concentrations of cefuroxime only in urine and not in serum or kidney tissue had no effect on kidney infection. Even low doses of gentamicin (0.05 mg/mouse) resulted in concentrations in renal tissue for prolonged times due to accumulation. All gentamicin doses had a significant effect (compared to the effect of the control treatment) on bacterial counts in urine and kidneys. The antibiotic effect on bacterial counts in bladders was negligible for unknown reasons. Use of the mouse UTI model is feasible for study of the effect of an antibiotic in the urinary system, although the missing antibacterial effect in the bladder needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10602738      PMCID: PMC89643          DOI: 10.1128/AAC.44.1.156-163.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.

Authors:  M A Mulvey; Y S Lopez-Boado; C L Wilson; R Roth; W C Parks; J Heuser; S J Hultgren
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

Review 2.  Short-term treatment of uncomplicated lower urinary tract infections in women.

Authors:  S R Norrby
Journal:  Rev Infect Dis       Date:  1990 May-Jun

3.  A review of models for the therapy of experimental infections.

Authors:  M G Bergeron
Journal:  Scand J Infect Dis Suppl       Date:  1978

4.  Detailed histopathological examination contributes to the assessment of Escherichia coli urovirulence.

Authors:  J R Johnson; T Berggren; D S Newburg; R H McCluer; J C Manivel
Journal:  J Urol       Date:  1992-04       Impact factor: 7.450

Review 5.  Virulence factors in Escherichia coli urinary tract infection.

Authors:  J R Johnson
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 6.  Diagnosis and drug treatment of acute pyelonephritis.

Authors:  A Meyrier; J Guibert
Journal:  Drugs       Date:  1992-09       Impact factor: 9.546

7.  Contribution of adhesion to bacterial persistence in the mouse urinary tract.

Authors:  L Hagberg; R Hull; S Hull; S Falkow; R Freter; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

Review 8.  Urinary tract infections in the 90s: pathogenesis and management.

Authors:  V T Andriole
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 9.  Duration of treatment of urinary tract infections.

Authors:  C M Kunin
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

Review 10.  [Treatment of urinary tract infections].

Authors:  P François
Journal:  Ann Pediatr (Paris)       Date:  1991-10
View more
  44 in total

1.  Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.

Authors:  Matthew G Blango; Matthew A Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

2.  Transurethral induction of mouse urinary tract infection.

Authors:  Kim H Thai; Anuradha Thathireddy; Michael H Hsieh
Journal:  J Vis Exp       Date:  2010-08-05       Impact factor: 1.355

Review 3.  Invasion of Host Cells and Tissues by Uropathogenic Bacteria.

Authors:  Adam J Lewis; Amanda C Richards; Matthew A Mulvey
Journal:  Microbiol Spectr       Date:  2016-12

4.  Detection of clonal group A Escherichia coli isolates from broiler chickens, broiler chicken meat, community-dwelling humans, and urinary tract infection (UTI) patients and their virulence in a mouse UTI model.

Authors:  Lotte Jakobsen; Anette M Hammerum; Niels Frimodt-Møller
Journal:  Appl Environ Microbiol       Date:  2010-10-29       Impact factor: 4.792

5.  Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway.

Authors:  Bijaya K Dhakal; Matthew A Mulvey
Journal:  J Biol Chem       Date:  2008-11-06       Impact factor: 5.157

6.  Role of urinary cathelicidin LL-37 and human β-defensin 1 in uncomplicated Escherichia coli urinary tract infections.

Authors:  Karen L Nielsen; Pia Dynesen; Preben Larsen; Lotte Jakobsen; Paal S Andersen; Niels Frimodt-Møller
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

Review 7.  Intracellular Bacterial Communities: A Potential Etiology for Chronic Lower Urinary Tract Symptoms.

Authors:  Victoria C S Scott; David A Haake; Bernard M Churchill; Sheryl S Justice; Ja-Hong Kim
Journal:  Urology       Date:  2015-07-15       Impact factor: 2.649

8.  Tetracycline rapidly reaches all the constituent cells of uropathogenic Escherichia coli biofilms.

Authors:  G Stone; P Wood; L Dixon; M Keyhan; A Matin
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  α-Intercalated cells defend the urinary system from bacterial infection.

Authors:  Neal Paragas; Ritwij Kulkarni; Max Werth; Kai M Schmidt-Ott; Catherine Forster; Rong Deng; Qingyin Zhang; Eugenia Singer; Alexander D Klose; Tian Huai Shen; Kevin P Francis; Sunetra Ray; Soundarapandian Vijayakumar; Samuel Seward; Mary E Bovino; Katherine Xu; Yared Takabe; Fábio E Amaral; Sumit Mohan; Rebecca Wax; Kaitlyn Corbin; Simone Sanna-Cherchi; Kiyoshi Mori; Lynne Johnson; Thomas Nickolas; Vivette D'Agati; Chyuan-Sheng Lin; Andong Qiu; Qais Al-Awqati; Adam J Ratner; Jonathan Barasch
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

10.  Interplay in the selection of fluoroquinolone resistance and bacterial fitness.

Authors:  Linda L Marcusson; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.